Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer

T. H. Cartwright, A. Cohn, J. A. Varkey, Y. M. Chen, T. P. Szatrowski, J. V. Cox, J. J. Schulz

Research output: Contribution to journalArticle

185 Scopus citations

Abstract

Purpose: To determine the safety and efficacy of capecitabine (Xeloda; Roche Laboratories, Nutley, NJ) in patients with metastatic or unresectable, locally advanced pancreatic cancer. Patients and Methods: Forty-two patients were treated with oral capecitabine 1,250 mg/m2 administered twice daily (2,500 mg/m2/d) as intermittent therapy in 3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment. Tumor lesions were assessed by computed tomography scan or physical examination at 6-week intervals (after every two cycles). Adverse events were monitored continuously during treatment and for 28 days after the last dose of study drug. Results: Ten (24%) of 42 patients experienced a clinical benefit response (95% confidence interval [Cl], 12.1 % to 39.5%) as evidenced by improvement in pain intensity, analgesic consumption, and/or Karnofsky performance status. Three (7.3%) of the 41 patients with measurable disease had an objective response (partial). The median time to objective response was 85 days (range, 47 to 91 days) and duration of response was 208, 260, and 566 days for the three responding patients. One patient with nonmeasurable but assessable disease had improved residual disease with a positive clinical benefit response, for a total of four responses among the 42 assessable patients, for an overall response rate of 9.5% (90% Cl, 3.3% to 20.5%). Capecitabine was generally well tolerated. Conclusion: Treatment with capecitabine resulted in clinically significant beneficial effects on tumor-related symptoms and yielded objective response activity in patients with metastatic or locally advanced pancreatic cancer. These results together with its generally tolerable safety profile and the added advantage of oral administration provide the basis for further evaluating capecitabine as a single agent or in combination with other treatment modalities in this patient population.

Original languageEnglish (US)
Pages (from-to)160-164
Number of pages5
JournalJournal of Clinical Oncology
Volume20
Issue number1
DOIs
StatePublished - Jan 1 2002

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer'. Together they form a unique fingerprint.

  • Cite this

    Cartwright, T. H., Cohn, A., Varkey, J. A., Chen, Y. M., Szatrowski, T. P., Cox, J. V., & Schulz, J. J. (2002). Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. Journal of Clinical Oncology, 20(1), 160-164. https://doi.org/10.1200/JCO.20.1.160